Brand Name

Nuzolvence

Generic Name
Zoliflodacin
View Brand Information
FDA approval date: December 22, 2025
Form: For

What is Nuzolvence (Zoliflodacin)?

NUZOLVENCE is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Extensively drug-resistant (XDR) Neisseria gonorrhoeae cured with ceftriaxone 2 g intravenous monotherapy in Croatia, March 2026.
Extensively drug-resistant (XDR) Neisseria gonorrhoeae cured with ceftriaxone 2 g intravenous monotherapy in Croatia, March 2026.
Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Published: May 29, 2026
Zoliflodacin for Urogenital Gonorrhea Infections.
Zoliflodacin for Urogenital Gonorrhea Infections.
Journal: The Annals of pharmacotherapy
Published: May 28, 2026
Fluoroquinolone resistance-conferring gyrA variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation gyrB D429N in Neisseria gonorrhoeae.
Fluoroquinolone resistance-conferring gyrA variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation gyrB D429N in Neisseria gonorrhoeae.
Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026
View All Latest Advances